{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:21:59Z","timestamp":1779916919328,"version":"3.53.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004099","name":"Ligue contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytidine deaminase (CDA), an enzyme of the pyrimidine salvage pathway, deaminates cytidine, deoxycytidine and analogs, such as gemcitabine. Constitutive low levels of CDA activity have been reported in the blood of patients with hematological malignancies or suffering from gemcitabine toxicity. We previously reported that cellular CDA deficiency leads to genetic instability. We therefore hypothesized that constitutive CDA deficiency might confer a predisposition to cancer. We analyzed CDA activity and expression in blood samples from breast cancer (BC) patients with a suspected predisposition to the disease, and in healthy controls. Contrary to our hypothesis, we found that both CDA activity and mRNA levels were higher in blood samples from BC patients than in those from controls, and that this difference was not due to excess neutrophils. CDA activity levels were significantly higher in the serum samples of BC patients treated by radiotherapy (RT) than in those of untreated healthy controls, and hormone therapy in RT-treated BC patients was associated with significantly lower levels of CDA activity. A preliminary analysis of CDA activity in the serum of the very few BC patients who had undergone no treatment other than surgery suggested that the increase in CDA activity might be due to the breast cancer itself. Our findings raise important questions, which should lead to studies to elucidate the origin and significance of the increase in CDA activity in the serum of BC patients, and the impact of hormone therapy.\n<\/jats:p>","DOI":"10.1038\/s41598-022-18462-8","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T13:02:56Z","timestamp":1660827776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytidine deaminase activity increases in the blood of breast cancer patients"],"prefix":"10.1038","volume":"12","author":[{"given":"G\u00e9raldine","family":"Buhagiar-Labarch\u00e8de","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosine","family":"Onclercq-Delic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bi\u00e8che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Stoppa-Lyonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Amor-Gu\u00e9ret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"18462_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s0167-4781(98)00235-8","volume":"1443","author":"S Demontis","year":"1998","unstructured":"Demontis, S. et al. Isolation and characterization of the gene coding for human cytidine deaminase. Biochim. Biophys. Acta 1443, 323\u2013333. https:\/\/doi.org\/10.1016\/s0167-4781(98)00235-8 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"18462_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0003-9861(91)90543-r","volume":"290","author":"T Cacciamani","year":"1991","unstructured":"Cacciamani, T. et al. Purification of human cytidine deaminase: Molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs. Arch. Biochem. Biophys. 290, 285\u2013292. https:\/\/doi.org\/10.1016\/0003-9861(91)90543-r (1991).","journal-title":"Arch. Biochem. Biophys."},{"key":"18462_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","volume":"28","author":"A Frances","year":"2020","unstructured":"Frances, A. & Cordelier, P. The emerging role of cytidine deaminase in human diseases: A new opportunity for therapy? Mol. Ther. 28, 357\u2013366. https:\/\/doi.org\/10.1016\/j.ymthe.2019.11.026 (2020).","journal-title":"Mol. Ther."},{"key":"18462_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2009.24.4491","volume":"28","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini, J. et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28, 160\u2013165. https:\/\/doi.org\/10.1200\/JCO.2009.24.4491 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"Pt B","key":"18462_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/978-1-4684-1248-2_65","volume":"195","author":"P Nygaard","year":"1986","unstructured":"Nygaard, P. On the role of cytidine deaminase in cellular metabolism. Adv. Exp. Med. Biol. 195(Pt B), 415\u2013420. https:\/\/doi.org\/10.1007\/978-1-4684-1248-2_65 (1986).","journal-title":"Adv. Exp. Med. Biol."},{"key":"18462_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/ncomms1363","volume":"2","author":"P Chabosseau","year":"2011","unstructured":"Chabosseau, P. et al. Pyrimidine pool imbalance induced by BLM helicase deficiency contributes to genetic instability in Bloom syndrome. Nat. Commun. 2, 368. https:\/\/doi.org\/10.1038\/ncomms1363 (2011).","journal-title":"Nat. Commun."},{"key":"18462_CR7","doi-asserted-by":"publisher","first-page":"e1005384","DOI":"10.1371\/journal.pgen.1005384","volume":"11","author":"S Gemble","year":"2015","unstructured":"Gemble, S. et al. Pyrimidine pool disequilibrium induced by a cytidine deaminase deficiency inhibits PARP-1 activity, leading to the under replication of DNA. PLoS Genet. 11, e1005384. https:\/\/doi.org\/10.1371\/journal.pgen.1005384 (2015).","journal-title":"PLoS Genet."},{"key":"18462_CR8","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1242\/jcs.187781","volume":"129","author":"S Gemble","year":"2016","unstructured":"Gemble, S. et al. A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. J. Cell Sci. 129, 3167\u20133177. https:\/\/doi.org\/10.1242\/jcs.187781 (2016).","journal-title":"J. Cell Sci."},{"key":"18462_CR9","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1080\/15384101.2017.1317413","volume":"16","author":"S Gemble","year":"2017","unstructured":"Gemble, S., Buhagiar-Labarchede, G., Onclercq-Delic, R., Jaulin, C. & Amor-Gueret, M. Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity. Cell Cycle 16, 1128\u20131135. https:\/\/doi.org\/10.1080\/15384101.2017.1317413 (2017).","journal-title":"Cell Cycle"},{"key":"18462_CR10","doi-asserted-by":"publisher","first-page":"13907","DOI":"10.1038\/s41598-020-70874-6","volume":"10","author":"SC Silveira","year":"2020","unstructured":"Silveira, S. C. et al. A decrease in NAMPT activity impairs basal PARP-1 activity in cytidine deaminase deficient-cells, independently of NAD(.). Sci. Rep. 10, 13907. https:\/\/doi.org\/10.1038\/s41598-020-70874-6 (2020).","journal-title":"Sci. Rep."},{"key":"18462_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.annonc.2021.01.072","volume":"32","author":"M Donnette","year":"2021","unstructured":"Donnette, M. et al. High incidence of CDA deficiency in patients with hematological malignancies: Perspectives and therapeutic implications. Ann. Oncol. 32, 684\u2013686. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.072 (2021).","journal-title":"Ann. Oncol."},{"key":"18462_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","volume":"19","author":"RZ Mahfouz","year":"2013","unstructured":"Mahfouz, R. Z. et al. Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res. 19, 938\u2013948. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1722 (2013).","journal-title":"Clin. Cancer Res."},{"key":"18462_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/15257770.2014.894196","volume":"33","author":"GJ Peters","year":"2014","unstructured":"Peters, G. J. et al. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids 33, 403\u2013412. https:\/\/doi.org\/10.1080\/15257770.2014.894196 (2014).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"18462_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/ard.50.6.362","volume":"50","author":"PS Helliwell","year":"1991","unstructured":"Helliwell, P. S., Marchesoni, A., Peters, M., Platt, R. & Wright, V. Cytidine deaminase activity, C reactive protein, histidine, and erythrocyte sedimentation rate as measures of disease activity in psoriatic arthritis. Ann. Rheum. Dis. 50, 362\u2013365. https:\/\/doi.org\/10.1136\/ard.50.6.362 (1991).","journal-title":"Ann. Rheum. Dis."},{"key":"18462_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/bcp.13849","volume":"85","author":"R Cohen","year":"2019","unstructured":"Cohen, R. et al. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. Br. J. Clin. Pharmacol. 85, 1227\u20131238. https:\/\/doi.org\/10.1111\/bcp.13849 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"18462_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/0284186X.2018.1529428","volume":"58","author":"C Wendt","year":"2019","unstructured":"Wendt, C. & Margolin, S. Identifying breast cancer susceptibility genes\u2014A review of the genetic background in familial breast cancer. Acta Oncol. 58, 135\u2013146. https:\/\/doi.org\/10.1080\/0284186X.2018.1529428 (2019).","journal-title":"Acta Oncol."},{"key":"18462_CR17","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-16-0626","volume":"23","author":"H Mameri","year":"2017","unstructured":"Mameri, H. et al. Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer. Clin. Cancer Res. 23, 2116\u20132126. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0626 (2017).","journal-title":"Clin. Cancer Res."},{"key":"18462_CR18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1182\/blood-2011-08-371690","volume":"119","author":"D Lavelle","year":"2012","unstructured":"Lavelle, D. et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 119, 1240\u20131247. https:\/\/doi.org\/10.1182\/blood-2011-08-371690 (2012).","journal-title":"Blood"},{"key":"18462_CR19","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","volume":"14","author":"GW Camiener","year":"1965","unstructured":"Camiener, G. W. & Smith, C. G. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem. Pharmacol. 14, 1405\u20131416. https:\/\/doi.org\/10.1016\/0006-2952(65)90175-9 (1965).","journal-title":"Biochem. Pharmacol."},{"key":"18462_CR20","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1080\/0284186X.2017.1348623","volume":"56","author":"A Schernberg","year":"2017","unstructured":"Schernberg, A., Blanchard, P., Chargari, C. & Deutsch, E. Neutrophils, a candidate biomarker and target for radiation therapy? Acta Oncol. 56, 1522\u20131530. https:\/\/doi.org\/10.1080\/0284186X.2017.1348623 (2017).","journal-title":"Acta Oncol."},{"key":"18462_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","volume":"4","author":"W Liang","year":"2016","unstructured":"Liang, W. & Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol. Res. 4, 83\u201391. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0313 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"18462_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3390\/cells10092486","volume":"10","author":"RV Sionov","year":"2021","unstructured":"Sionov, R. V. Leveling up the controversial role of neutrophils in cancer: When the complexity becomes entangled. Cells 10, 2486. https:\/\/doi.org\/10.3390\/cells10092486 (2021).","journal-title":"Cells"},{"key":"18462_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: Neutral no more. Nat. Rev. Cancer 16, 431\u2013446. https:\/\/doi.org\/10.1038\/nrc.2016.52 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"18462_CR24","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ 362, k3519. https:\/\/doi.org\/10.1136\/bmj.k3519 (2018).","journal-title":"BMJ"},{"key":"18462_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/FPC.0b013e32825ea6e3","volume":"17","author":"C Mercier","year":"2007","unstructured":"Mercier, C. et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics 17, 841\u2013844. https:\/\/doi.org\/10.1097\/FPC.0b013e32825ea6e3 (2007).","journal-title":"Pharmacogenet. Genomics"},{"key":"18462_CR26","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1038\/sj.onc.1204917","volume":"20","author":"I Bieche","year":"2001","unstructured":"Bieche, I. et al. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 20, 8109\u20138115. https:\/\/doi.org\/10.1038\/sj.onc.1204917 (2001).","journal-title":"Oncogene"},{"key":"18462_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i07","volume":"42","author":"JS Sekhon","year":"2011","unstructured":"Sekhon, J. S. Multivariate and propensity score matching software with automated balance optimization: The matching package for R. J. Stat. Softw. 42, 1\u201352. https:\/\/doi.org\/10.18637\/jss.v042.i07 (2011).","journal-title":"J. Stat. Softw."}],"updated-by":[{"DOI":"10.1038\/s41598-022-23982-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18462-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18462-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18462-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T18:24:49Z","timestamp":1670523889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18462-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18462"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18462-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-022-23982-4","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-23982-4","URL":"https:\/\/doi.org\/10.1038\/s41598-022-23982-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14062"}}